WeGovy and Ozempic are both weight loss drugs that belong to the GLP-1 agonist class of drugs. GLP-1 agonists work by mimicking the hormone GLP-1, which helps regulate blood sugar levels and suppresses appetite. Both drugs have been approved by the FDA for weight loss in adults with obesity or overweight and at least one weight-related condition.

One potential advantage of WeGovy over Ozempic is that it has been shown to lead to greater weight loss in clinical trials. According to a study cited by UCHealth [2], patients taking WeGovy lost an average of 16.0% of their body weight, compared to 9.3% for patients taking Ozempic. Additionally, WeGovy was more effective at reducing HbA1c levels, a measure of blood sugar control, than Ozempic.

However, there are also some potential downsides to WeGovy. It is a newer drug and therefore may be more expensive than Ozempic. Additionally, it requires weekly injections for the first 16 weeks, whereas Ozempic only requires once-weekly injections [3]. Some patients may find the more frequent injections to be a disadvantage.

In summary, WeGovy may have an advantage over Ozempic in terms of greater weight loss and better blood sugar control, but it may also be more expensive and require more frequent injections. Patients should discuss the potential benefits and drawbacks of each drug with their healthcare provider to determine which option is best for them.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.uchealth.org/today/wegovy-vs-ozempic-the-truth-about-new-weight-loss-drugs/
[3] https://www.goodrx.com/classes/glp-1-agonists/wegovy-vs-ozempic